BOSTON and ROLLE, Switzerland, June 19, 2026
SOPHiA GENETICS, a global leader in AI-driven precision medicine, has announced the successful closing of a $57.5 million underwritten public offering, marking a significant financial milestone that strengthens the company’s position in the rapidly expanding intersection of artificial intelligence, genomics, and healthcare analytics. The offering exceeded expectations, attracting strong investor demand and resulting in the full exercise of the underwriters’ option to purchase additional shares. In total, the company sold 12.1 million ordinary shares at a public offering price of $4.75 per share, generating gross proceeds of approximately $57.5 million before underwriting discounts, commissions, and related expenses. The successful capital raise underscores growing investor confidence in the company’s mission to transform healthcare through advanced data-driven technologies capable of improving diagnosis, treatment selection, and clinical decision-making across oncology, rare diseases, and biopharmaceutical research.
Strong Investor Demand Highlights Confidence in AI-Powered Medicine
The public offering was led by TD Cowen with participation from Guggenheim Securities, BTIG, and Craig-Hallum. The transaction was oversubscribed, reflecting strong market interest in companies leveraging artificial intelligence to address complex healthcare challenges. Investor enthusiasm continues to grow around organizations capable of integrating genomic information, multimodal healthcare data, and advanced analytics into actionable clinical insights. SOPHiA GENETICS has positioned itself at the forefront of this transformation through its proprietary SOPHiA DDM™ platform, an AI-native technology that analyzes complex genomic and multimodal datasets to generate real-time, clinically relevant insights.
The platform supports a broad global network of hospitals, laboratories, and biopharmaceutical organizations, helping healthcare providers improve precision medicine initiatives while enhancing research and patient care outcomes. The successful financing provides additional resources to support continued innovation, platform expansion, and global commercialization efforts.
SOPHiA DDM™ Platform Advances Precision Medicine Innovation
Advertisement
As healthcare systems increasingly adopt precision medicine approaches, the ability to efficiently interpret large volumes of biological and clinical data has become critical. SOPHiA GENETICS’ flagship SOPHiA DDM™ platform combines artificial intelligence, machine learning, and advanced analytics to identify clinically meaningful patterns across genomic, molecular, and multimodal healthcare datasets. The platform supports applications spanning oncology, rare and inherited diseases, molecular diagnostics, and biopharmaceutical research. By enabling healthcare organizations to transform complex data into actionable insights, SOPHiA GENETICS aims to accelerate diagnosis, optimize treatment strategies, and improve patient outcomes.
The company’s technology has gained recognition for helping institutions navigate the growing complexity of genomic medicine while supporting more personalized approaches to healthcare delivery. As demand for AI-powered healthcare solutions continues to expand globally, SOPHiA GENETICS remains focused on advancing technologies that bridge the gap between scientific data and clinical action.
Funding Supports Long-Term Growth in Digital Health and Genomics
The newly completed financing strengthens SOPHiA GENETICS’ ability to pursue strategic growth initiatives across key healthcare markets while continuing to invest in research, development, and commercialization activities. The company operates within one of the fastest-growing sectors of healthcare, where artificial intelligence is increasingly being applied to genomic analysis, biomarker discovery, clinical decision support, and precision medicine programs. Industry experts expect AI-enabled healthcare technologies to play a critical role in the future of diagnostics and personalized treatment planning, creating significant opportunities for companies with proven platforms and scalable infrastructure.
The successful offering not only enhances SOPHiA GENETICS’ financial flexibility but also reinforces its position as a leading innovator in AI-driven healthcare. As the company continues expanding its global network of healthcare, laboratory, and biopharma partners, the additional capital is expected to support its mission of making data-driven medicine more accessible, actionable, and impactful for patients worldwide.
Source: SOPHiA GENETICS press release
